AZD9833
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-negative Breast Cancer
Conditions
HER2-negative Breast Cancer
Trial Timeline
Nov 2, 2020 → Jun 19, 2023
NCT ID
NCT04588298About AZD9833
AZD9833 is a phase 2 stage product being developed by AstraZeneca for HER2-negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04588298. Target conditions include HER2-negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04588298 | Phase 2 | Completed |
| NCT04541433 | Phase 1 | Completed |
Competing Products
19 competing products in HER2-negative Breast Cancer